GRI Bio (GRI) Expected to Announce Quarterly Earnings on Friday

GRI Bio (NASDAQ:GRI) is expected to release its results before the market opens on Friday, March 13th. Analysts expect GRI Bio to post earnings of ($29.27) per share for the quarter.

GRI Bio (NASDAQ:GRI) last issued its quarterly earnings data on Friday, January 30th. The company reported $23.52 earnings per share for the quarter. On average, analysts expect GRI Bio to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

GRI Bio Stock Performance

Shares of NASDAQ:GRI opened at $2.40 on Friday. The company has a market capitalization of $3.48 million, a price-to-earnings ratio of -0.01 and a beta of -1.38. GRI Bio has a 12-month low of $2.10 and a 12-month high of $311.36. The business has a 50-day moving average price of $4.53 and a 200 day moving average price of $31.40.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on GRI shares. Wall Street Zen lowered GRI Bio to a “strong sell” rating in a report on Saturday, January 31st. Weiss Ratings reiterated a “sell (e+)” rating on shares of GRI Bio in a research note on Thursday, January 22nd. Finally, Ascendiant Capital Markets upped their price target on GRI Bio from $980.00 to $1,008.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $644.00.

GRI Bio Company Profile

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.